Inventory: drug enterprise M & A cases with transaction amount exceeding 10 billion US dollars in 2019

[pharmaceutical network industry trends] looking back on the past 2019, this is a year of vigorous development of global pharmaceutical industry M & A, and there have been many large-scale M & A transactions of pharmaceutical enterprises around the world In this regard, the author combs the public information and makes an inventory of the drug enterprise M & A transactions with a transaction amount of more than 10 billion US dollars in 2019 Bristol Myers Squibb's acquisition of Xinji transaction amount: US $74 billion event description: on January 3, 2019, Bristol Myers Squibb announced that it would acquire Xinji at a total price of US $74 billion in cash and shares This is a very large-scale pharmaceutical industry acquisition in history, combining two cancer drug manufacturers On November 21, 2019, Bristol Myers Squibb announced that the company has successfully completed the acquisition of Xinji According to the M & a agreement, after the completion of the acquisition, Xinji became a wholly-owned subsidiary of Bristol Myers Squibb At present, Bristol Myers Squibb is a global leader in the development of innovative drugs for the treatment of cardiovascular diseases, metabolic and infectious diseases, central nervous system diseases, skin diseases and cancer, with an annual sales volume of more than 20 billion US dollars Abwi's acquisition of Elgin transaction amount: US $63 billion event description: in June 2019, the pharmaceutical giant announced to invest about US $63 billion to acquire Elgin With this acquisition, abwi hopes to set foot in fast-growing markets such as medical cosmetology and eye care It is reported that if the acquisition is completed, the new company will be based on the company's Humira and its flagship beauty care drug Botox Amgen's acquisition of new base otezla transaction amount: US $13.4 billion event description: in August 2019, Amgen announced to acquire the global equity of new base psoriasis new drug otezla with us $13.4 billion cash It is reported that after the completion of this acquisition, Amgen will obtain the global distribution right of apopst and continue to expand the international market of the drug On November 15, 2019, Bristol Myers Squibb announced that FTC has accepted the consent order proposed by the company for its pending merger with Xinji and allowed both parties to complete the merger Bristol Myers Squibb expects the divestiture of otezla to be completed as soon as possible after the completion of the acquisition, and plans to prioritize this part of the profits for debt reduction Pfizer puqiang and mylan merged into a new company with a transaction amount of US $12 billion Event description: on July 30, 2019, Pfizer and mylan jointly announced an agreement to merge Pfizer's mature pharmaceutical business departments puqiang and mylan to establish a new multinational pharmaceutical enterprise Upon completion of the transaction, Pfizer shareholders will hold 57% of the shares of the new company after the merger, and mylan shareholders will hold 43% of the shares of the new company after the merger It is reported that Pfizer will bring famous brands such as Lipitor (atorvastatin calcium), Celebrex (celecoxib) and sildenafil into the new company The new company is expected to generate $19-20 billion in revenue by 2020 Then on November 12, 2019, Pfizer announced the name of viatris, a new company formed by the merger of Pfizer's subsidiary Pfizer puqiang and mylan Pfizer's acquisition of array company transaction amount: US $11.4 billion event description: on June 17, 2019, Pfizer and array biopharmaceutical Co., Ltd jointly announced that they had reached an agreement that Pfizer would acquire array in full cash at US $48 per share, with a total transaction amount of about US $11.4 billion It is understood that the main products on the market of array company are the combination therapy braftovi (encorafenib) + mektovi (binimetinib), which was approved by FDA on June 28, 2018, to treat the mutation of BRAFV600E or brafv600k It is understood that the acquisition aims to expand Pfizer's Oncology business and sales channels.